Tirzepatide: 10MG

£44.99

Purity: ≥ 99%

£44.99

Tirzepatide: 10MG

Name: Tirzepatide: 10MG
Brand: Pure Grade Labs
Price: 44.99 GBP
Availability: OutOfStock

£44.99

Purity: ≥ 99%

£44.99

BODY COMPOSITION - Weight loss & visceral fat reduction research

CARDIOVASCULAR - Heart health & cardiometabolic research

HEPATIC - Liver fat & NASH/MASH reduction research

GLYCAEMIC - Blood sugar & glucose regulation research

Tirzepatide (LY3298176) is a synthetic 39-amino acid peptide that simultaneously activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Developed by Eli Lilly, it is structurally based on the native GIP sequence, with modifications enabling dual receptor engagement. A C20 fatty diacid moiety is attached via a linker to enable albumin binding, extending its half-life to approximately 5 days and allowing once-weekly subcutaneous dosing. Researchers describe it as a "twincretin" - a single unimolecular dual agonist that does the work of two incretin hormones.

Mechanistically, tirzepatide's GIP and GLP-1 components are imbalanced - cryo-EM structural analysis has confirmed that it engages the GIPR with greater potency relative to the GLP-1R at clinically relevant concentrations, while its interaction with GLP-1R produces less agonist-induced receptor desensitisation than pure GLP-1 agonists like semaglutide. This pharmacological profile may explain its superior weight loss outcomes in head-to-head comparisons. Tirzepatide received FDA approval for type 2 diabetes (Mounjaro, 2022) and obesity (Zepbound, 2023). In the SURMOUNT-1 trial, the highest dose produced 22.5% mean body weight reduction over 72 weeks - the largest weight loss recorded in any pharmaceutical trial at the time of publication.

Dual Mechanism: Simultaneous GIPR and GLP-1R agonism. GIP component enhances insulin secretion, modulates adipose tissue function, and activates central reward signals related to food. GLP-1 component suppresses appetite centrally, delays gastric emptying, and suppresses glucagon. The combined effect exceeds either pathway alone.

Research Context: Phase 3 SURPASS programme: 10 trials, 6,000+ patients with T2D. Phase 3 SURMOUNT programme: obesity trials with up to 2,539 participants per study. FDA approved 2022/2023. Head-to-head data against semaglutide 1mg shows superior HbA1c and weight outcomes at all doses. Strongest weight loss data of any FDA-approved medication as of April 2026.

Structural Features: 39-residue GIP-based sequence | C20 fatty diacid moiety via gamma-Glu-mini-PEG linker at Lys-34 | Aib substitution at position 2 (DPP-4 resistance) | Imbalanced dual agonism: GIPR > GLP-1R | Half-life ~5 days

Peptide Length: 39 Amino Acids

Molecular Weight: 4,813.5 g/mol

CAS Number: 2023788-19-2

Form: Lyophilised Solid

The following summaries are drawn from peer-reviewed publications. Tirzepatide's clinical evidence base includes Phase 3 data from 10 SURPASS trials (T2D) and the SURMOUNT obesity programme, involving over 13,000 participants. Pure Grade Labs does not interpret these findings as evidence of efficacy in humans outside of their stated research contexts.

New England Journal of Medicine (SURPASS-2): SURPASS-2: Tirzepatide outperforms semaglutide 1mg on HbA1c and weight loss in head-to-head trial (n=1,879)

New England Journal of Medicine (SURMOUNT-1): SURMOUNT-1: Tirzepatide 15mg produces 22.5% mean weight reduction over 72 weeks in adults with obesity (n=2,539)

Science / Nature Communications (Structural Pharmacology): Cryo-EM structural analysis reveals tirzepatide's imbalanced dual receptor pharmacology and reduced GLP-1R desensitisation

References

https://pubmed.ncbi.nlm.nih.gov/38078870/

https://pubmed.ncbi.nlm.nih.gov/39536238/

https://pubmed.ncbi.nlm.nih.gov/39497468/

https://pubmed.ncbi.nlm.nih.gov/39996368/

https://pubmed.ncbi.nlm.nih.gov/40365662/

https://pmc.ncbi.nlm.nih.gov/articles/PMC10159347/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11576767/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12469573/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12579026/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12232368/

Every batch of Tirzepatide supplied by Pure Grade Labs is accompanied by a Certificate of Analysis (COA) from an independent third-party analytical laboratory. The COA confirms identity, purity by HPLC, and absence of contaminants. Batch-specific documentation is linked below.

Tirzepatide is supplied as a lyophilised (freeze-dried) solid. Correct handling is essential to preserve the integrity of this dual-modified peptide. Follow the specifications below.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow the sealed vial to reach room temperature before opening to minimise condensation and moisture introduction.
Use bacteriostatic water (BAC water) as the reconstitution solvent. Add solvent slowly down the inside wall of the vial - do not inject directly onto the lyophilised cake.
Gently swirl until fully dissolved. Do not vortex or shake vigorously. Tirzepatide contains a fatty acid chain that requires careful handling to preserve structural integrity.
Inspect the solution: it should be clear and colourless. Discard if cloudy, discoloured, or contains particulate matter.
Once reconstituted, store at 2-8°C. Use within 28 days. Do not freeze reconstituted solution.

Tirzepatide supplied by Pure Grade Labs is intended exclusively for in vitro research and laboratory use. While tirzepatide is FDA-approved under the brand names Mounjaro and Zepbound for specific clinical indications, the research-grade compound supplied here is not equivalent to those approved pharmaceutical products and is not approved for human administration.

This product is not a drug, medicine, or supplement and must not be used as such outside of a licensed clinical or research context.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans for any use of this research compound.
Tirzepatide is a prescription-only medicine in all jurisdictions where it is approved. Purchase and self-administration outside of a licensed prescriber relationship is subject to regulatory restrictions and may be illegal in your jurisdiction.
Tirzepatide is prohibited in sport by WADA under the S4 Hormone and Metabolic Modulators category. Athletes subject to drug testing must be aware of this classification.
Known safety signals include gastrointestinal adverse events (nausea, vomiting, diarrhoea, constipation), gallbladder-related disorders, and a black box warning regarding thyroid C-cell tumour risk in individuals with a history of medullary thyroid carcinoma or MEN2.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All product information, research summaries, and study citations presented on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.